- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Thromboembolism, Vaginal Cancer, Vulvar Cancer
- Interventions
- fondaparinux sodium
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Upland, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 552
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Deep Venous Thrombosis, Post-thrombotic Syndrome
- Interventions
- PET/CT
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pulmonary Embolism
- Interventions
- Denali inferior vena cava filter
- Device
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 18 more
- Conditions
- Sepsis, Venous Thromboembolism, Disseminated Intravascular Coagulation
- Interventions
- Diagnosis of both VTE and sepsis
- Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Traumatic Brain Injury, Venous Thromboembolism
- Interventions
- Observational, Observational-control
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15,000 participants
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Artificial Heart Valve
- Interventions
- Genotype-guided dose determination, Non-genotype guided warfarin dosing
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Pulmonary Embolism, Thrombotic Disease
- Interventions
- DS-1040b, Placebo, Enoxaparin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 15
- States / cities
- Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more
- Conditions
- Anemia, Venous Thrombosis
- Interventions
- blood sampling
- Other
- Lead sponsor
- Matthew Neal MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Venous Thromboembolism
- Interventions
- dabigatran etexilate, standard of care
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 9
- States / cities
- Sacramento, California • Miami, Florida • Tampa, Florida + 6 more
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus
- Interventions
- Twice daily enoxaparin prophylaxis, Real time dose adjustment
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Interventions
- Abelacimab, Apixaban
- Biological · Drug
- Lead sponsor
- Anthos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 23
- States / cities
- Aurora, Colorado • West Haven, Connecticut • Washington D.C., District of Columbia + 19 more
- Conditions
- Venous Thromboembolism, Arterial Thromboembolism
- Interventions
- IMPROVE DD VTE Tool
- Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 10,699 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Manhasset, New York • New Hyde Park, New York • New York, New York + 1 more
- Conditions
- Sickle Cell Disease, Venous Thrombosis, Sickle Cell Trait, Hypercoagulable State, Venous Thromboembolism
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Embolism, Venous Thromboembolism
- Interventions
- Günther Tulip Vena Cava Filter
- Device
- Lead sponsor
- Cook Group Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 17
- States / cities
- Newark, Delaware • Washington D.C., District of Columbia • Miami, Florida + 13 more
- Conditions
- Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
- Interventions
- ActiveCare CECT device, Enoxaparin
- Device · Drug
- Lead sponsor
- Medical Compression Systems
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 9
- States / cities
- La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more
- Conditions
- Deep Vein Thrombosis
- Interventions
- Exercise
- Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
- Interventions
- EYE103, Aflibercept 2.0 mg
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 55
- States / cities
- Scottsdale, Arizona • Glendale, California • Modesto, California + 34 more
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Dilated Cardiomyopathies
- Interventions
- Financial Incentive and Med-eMonitor, 2Med-eMonitor
- Behavioral · Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Deep Venous Thromboses, Pulmonary Embolism, Venous Thromboembolism
- Interventions
- DDimer test
- Diagnostic Test
- Lead sponsor
- Diagnostica Stago
- Industry
- Eligibility
- Up to 79 Years
- Enrollment
- 5,935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Indianapolis, Indiana + 9 more
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 8,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
- Conditions
- Thromboembolism
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Boston, Massachusetts
- Conditions
- Venous Thromboembolism
- Interventions
- Not listed
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 14,799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Gynecologic Cancer, Venous Thromboembolism
- Interventions
- Oral apixaban, Subcutaneous enoxaparin
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Aurora, Colorado